Picture of Aptorum logo

APM Aptorum Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapFalling Star

Momentum

Relative Strength (%)
1m-20.64%
3m-19.16%
6m-61.2%
1yr-73.96%
Volume Change (%)
10d/3m+87.47%
Price vs... (%)
52w High-76.78%
50d MA-1.47%
200d MA-48.45%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-114.89%
Return on Equity-40.08%
Operating Margin-1269.22%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Aptorum EPS forecast chart

Profile Summary

Aptorum Group Limited is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's segments include Therapeutics and Non-Therapeutics. Therapeutics segment is seeking to develop various drug molecules (including projects seeking to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment of human disease conditions to tackle unmet needs, in particular, two of its lead projects targeting infectious disease and cancer (including orphan oncology indications). Non-Therapeutics segment encompasses three businesses, such as diagnostics projects, including a molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology, natural supplements, including NativusWell, and AML Clinic.

Directors

Last Annual
December 31st, 2021
Last Interim
June 30th, 2022
Incorporated
January 1st, 1970
Public Since
December 18th, 2018
No. of Shareholders
27
No. of Employees
26
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
23,764,304.3
Blurred out image of a map
Address
17 Hanover Square, LONDON, W1S 1BN
Web
http://www.aptorumgroup.com/
Phone
+44 2080929299
Auditors
Marcum Bernstein & Pinchuk LLP

APM Share Price Performance

Upcoming Events for APM

Similar to APM

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of Alimera Sciences logo

Alimera Sciences

us flag iconNASDAQ Global Market

Picture of ANI Pharmaceuticals logo

ANI Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Aquestive Therapeutics logo

Aquestive Therapeutics

us flag iconNASDAQ Global Market

Picture of Avadel Pharmaceuticals logo

Avadel Pharmaceuticals

us flag iconNASDAQ Global Market

FAQ

Or unlock with your email

Or unlock with your email